New Heart Failure Guidelines Recommend Semaglutide and Tirzepatide
The European Society of Cardiology's 2026 heart failure guidelines, published August 28, recommend semaglutide or tirzepatide for patients with preserved ejection fraction and obesity, and erase the middle ejection fraction category that has shaped treatment decisions for years.







